Cystic fibrosis, a genetic disorder, affects lungs and other organs. It causes thick mucus buildup. Researchers have ...
A research team led by Dr. Àlex Bayés, Head of the Molecular Physiology of the Synapse Group at the Institut de Recerca Sant ...
In the last few years, progress has been made in the fight against Alzheimer's disease with a class of therapies called ...
Confused about protein recommendations? We asked protein experts on what exactly is the answer. Plus, everything else you ...
Patients whose cancers were hormone receptor (HR) negative – that is, their tumor cells did not have proteins that bind to ...
A research team at Florida State University's Institute of Molecular Biophysics and Department of Chemistry and Biochemistry ...
Two scientists at the Johns Hopkins School of Medicine have been selected for membership in the National Academy of Inventors ...
This research led to Balu-Iyer founding the Buffalo-based company Immune Modulatory Therapies LLC in 2019. His UB co-founders ...
The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors ...
Trastuzumab deruxtecan (T-DXd; Enhertu), is a HER2-targeting ADC that is used in ET-treated HER2-low or HER2-ultralow disease and offered meaningful results in DESTINY-Breast04. In a 2025 real-world ...
Explore the full archive of TIME, a century of journalism, insight, and perspective, with AI that helps you research, connect ...
Discover Vor BiopharmaVor Biopharma Inc.'s potential with telitacicept amid funding challenges and market risks. Click for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback